Last reviewed · How we verify

NCT04968795

Heartfulness Meditation and Corporate Burnout

Status unknown Last updated 8 October 2021
What this trial tests

trial testing Heartfulness Meditation in Burnout in 150 participants. Status unknown.

Timeline
1 May 2021
Primary endpoint
30 April 2022
1 July 2022

Quick facts

Lead sponsorResolution Blue Labs Inc
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 May 2021
Primary completion30 April 2022
Estimated completion1 July 2022
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Resolution Blue Labs Inc

Who can join

Adults 18 to 75, any sex, with Burnout or Meditation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of a 4-week heart-based meditation practice wellness workshop on burnout and emotional wellness in corporate employees. Corporate employees can be defined as individuals who work in large institutions with greater than 300 employees. The specific aim of this study is to assess changes in scores measuring symptoms of emotional exhaustion, depersonalization, and personal accomplishment using the Maslach Burnout Index. We hypothesize that the meditation wellness practice will be associated with reduction in burnout for those who take part in the meditation program in comparison to the participants who did not meditate and participate in the wellness program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Heartfulness Meditation

Trials testing the same drug.

Other recruiting trials for Burnout

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04968795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing